WuXi Biologics and ABL Bio have entered into an exclusive development and clinical manufacturing partnership for multiple bispecific antibodies.
The partnership is for up to 8 antibody therapeutics including ABL Bio’s biologics pipelines and collaboration programs between ABL Bio and I-Mab Biopharma (I-Mab).
The agreement showcases the expansive biologics pipeline of ABL Bio and the world leading technical expertise and capabilities of WuXi Biologics in developing bispecific programs.
ABL Bio CEO Dr. Sang Hoon Lee said: “We are very pleased to enter into this partnership with WuXi Biologics. The partnership with WuXi Biologics is an important strategy for growing our internal and external programs of next-generation of biologics such as bispecific antibody. WuXi Biologics has enabled several preclinical and clinical manufacturing programs for ABL Bio as well as collaboration with I-Mab.
“I believe that the partnership with WuXi Biologics will bring a synergy effect for developing our bispecific antibody pipelines and help us step up to be a global top-tier biotechnology company for immuno-oncology and neurodegenerative disease treatment.”
WuXi Biologics CEO Dr. Chris Chen said: “We are excited about this exclusive partnership, our first in South Korea. WuXi Biologics has been well recognized as a global leader in the development and manufacturing of difficult biologics such as bispecific antibodies.
“This agreement continues to exemplify our technical strength and unparalleled capacity in global biologics development and manufacturing.
“We are able to initiate 60 IND-enabling programs and 3 BLA-enabling programs per year, enabled by one of the largest biologics development teams in the industry of approximately 2000 scientists. With globally recognized technical capabilities and unparalleled capacities, we are transforming how biologics are developed in the global setting.”
Source: Company Press Release